Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

14 nov. 2016 16h30 HE | Source: Cellceutix Corporation

Cellceutix Provides Corporate Update and Reports Q1 Fiscal 2017 Financial Results

Enrollment Underway in Phase 2b Study of Prurisol for Moderate to Severe Plaque Psoriasis Positive Initial Data Reported in Phase 2a Proof of Concept Open-Label Study of Brilacidin...
09 nov. 2016 07h30 HE | Source: Cellceutix Corporation

Cellceutix Announces Business Update Call at 10AM Eastern on November 15

BEVERLY, Mass., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Cellceutix Corporation (OTCQB:CTIX) (the “Company”), a clinical stage biopharmaceutical company developing innovative therapies including...
31 oct. 2016 15h07 HE | Source: Cellceutix Corporation

Cellceutix Begins Phase 2b Clinical Trial of Oral Prurisol in Moderate-to-Severe Chronic Plaque Psoriasis

BEVERLY, Mass., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology,...
26 oct. 2016 07h30 HE | Source: Cellceutix Corporation

Cellceutix Novel Anti-Inflammatory Phase 2 Drug Candidate Brilacidin Builds Momentum Across Multiple Clinical Indications

BEVERLY, Mass., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology,...
10 oct. 2016 07h00 HE | Source: Cellceutix Corporation

Cellceutix Phase 2 Trial Initial Data Shows Potential of Brilacidin as a Novel Anti-Inflammatory Drug Candidate for the Induction of Remission of Mild-to-Moderate Ulcerative Colitis

BEVERLY, Mass., Oct. 10, 2016 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTC: CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology,...